|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
|
|
|
|
|
Item 8.01 |
Other Events.
|
Item 9.01 |
Financial Statements and Exhibits.
|
Exhibit
No.
|
Description
|
|
99.1
|
Press Release of Bristol-Myers Squibb Company, dated November 5, 2019.
|
|
104
|
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
|
Exhibit
No.
|
Description
|
|
Press Release of Bristol-Myers Squibb Company, dated November 5, 2019.
|
||
104
|
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
|
BRISTOL-MYERS SQUIBB COMPANY
|
|||
Dated: November 5, 2019
|
By:
|
/s/ Katherine R. Kelly
|
|
Name:
|
Katherine R. Kelly
|
||
Title:
|
Corporate Secretary
|
Celgene Notes Tendered as of
|
||||||||||||
Aggregate
|
5:00 p.m., New York City
|
|||||||||||
Principal
|
time, on November 4, 2019
|
|||||||||||
Amount
|
Principal
|
|||||||||||
Title of Series
|
CUSIP Number
|
Outstanding
|
Amount
|
Percentage
|
||||||||
2.875% Senior Notes due 2020
|
151020AQ7
|
$
|
1,500,000,000
|
$
|
1,043,366,000
|
69.56%
|
|
|||||
3.950% Senior Notes due 2020
|
151020AE4
|
$
|
500,000,000
|
$
|
435,801,000
|
87.16%
|
|
|||||
2.875% Senior Notes due 2021
|
151020BC7
|
$
|
500,000,000
|
$
|
429,027,000
|
85.81%
|
|
|||||
2.250% Senior Notes due 2021
|
151020AV6
|
$
|
500,000,000
|
$
|
439,885,000
|
87.98%
|
|
|||||
3.250% Senior Notes due 2022
|
151020AH7
|
$
|
1,000,000,000
|
$
|
825,342,000
|
82.53%
|
|
|||||
3.550% Senior Notes due 2022
|
151020AR5
|
$
|
1,000,000,000
|
$
|
878,750,000
|
87.88%
|
|
|||||
2.750% Senior Notes due 2023
|
151020AX2
|
$
|
750,000,000
|
$
|
620,950,000
|
82.79%
|
|
|||||
3.250% Senior Notes due 2023
|
151020BA1
|
$
|
1,000,000,000
|
$
|
905,340,000
|
90.53%
|
|
|||||
4.000% Senior Notes due 2023
|
151020AJ3
|
$
|
700,000,000
|
$
|
627,674,000
|
89.67%
|
|
|||||
3.625% Senior Notes due 2024
|
151020AP9
|
$
|
1,000,000,000
|
$
|
869,522,000
|
86.95%
|
|
|||||
3.875% Senior Notes due 2025
|
151020AS3
|
$
|
2,500,000,000
|
$
|
2,362,709,000
|
94.51%
|
|
|||||
3.450% Senior Notes due 2027
|
151020AY0
|
$
|
1,000,000,000
|
$
|
944,705,000
|
94.47%
|
|
|||||
3.900% Senior Notes due 2028
|
151020BB9
|
$
|
1,500,000,000
|
$
|
1,406,356,000
|
93.76%
|
|
|||||
5.700% Senior Notes due 2040
|
151020AF1
|
$
|
250,000,000
|
$
|
244,732,000
|
97.89%
|
|
|||||
5.250% Senior Notes due 2043
|
151020AL8
|
$
|
400,000,000
|
$
|
390,643,000
|
97.66%
|
|
|||||
4.625% Senior Notes due 2044
|
151020AM6
|
$
|
1,000,000,000
|
$
|
922,257,000
|
92.23%
|
|
|||||
5.000% Senior Notes due 2045
|
151020AU8
|
$
|
2,000,000,000
|
$
|
1,916,762,000
|
95.84%
|
|
|||||
4.350% Senior Notes due 2047
|
151020AW4
|
$
|
1,250,000,000
|
$
|
1,141,280,000
|
91.30%
|
|
|||||
4.550% Senior Notes due 2048
|
151020AZ7
|
$
|
1,500,000,000
|
$
|
1,343,559,000
|
89.57%
|
|
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end
Q(
M(^2N,."*\TMA\D@C1*\PY8I#3&'X2".ECU%7G&1BZ0.-E#[F77&